As an example, in a very recent study, Madic et al. used the high prevalence of TP53 mutations in triple negative breast cancer (TNBC) to compare ctDNA and CTCs detection rates and evaluate their prognostic value in metastatic TNBC patients [45]. This evidence concerns the gene TP53 and triple-negative breast carcinoma.